CA 125

This version of the course is no longer available.
Need multiple seats for your university or lab? Get a quote
The page below is a sample from the LabCE course Tumor Markers (retired 12/7/2020). Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Tumor Markers (retired 12/7/2020) (online CE course)
CA 125

CA 125 falls short of being an ideal tumor marker in that it lacks the specificity required to be used as an effective screening tool.
  • CA 125 is a mucin tumor marker that is produced primarily by ovarian and endothelial cells.
  • Because CA 125 is sometimes produced by non-cancerous endothelial cells of the uterine endothelium, it is not recommended as a screening test for ovarian cancer in non-symptomatic women.
  • CA 125 is also produced by some non-ovarian carcinomas of the pancreas, lung, breast, and colon.
  • CA 125 is produced with an incidence of over 90% in cases of advanced ovarian cancer, and thus has been used to assist in the diagnosis of ovarian cancer in symptomatic women.6
  • Persistently elevated levels of CA 125 after chemotherapy are indicative of a poor prognosis.
  • CA 125 is also used to monitor the effectiveness of ovarian cancer treatments, to assess the prognosis of a patient, and to determine recurrence or relapse from a state of remission.7